Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .

Essential

These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.
Statistics

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external video platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name Youtube
Purpose External media

Leukemic Stem Cells

Activation of Leukemic Stem Cells

Leukemias are thought to be sustained by quiescent leukemic stem cells (LSCs), which can transplant the disease and show unlimited self-renewal activity. As for HSCs, LSCs appear to be resistant to conventional chemotherapy. The mechanisms responsible for this resistance remain unclear, however their quiescent or even dormant status, as well as their localization within a protective bone marrow niche, are likely critical components contributing towards therapy resistance. In our group we are investigating whether resistant LSCs can be targeted by driving them out of dormancy or mobilizing them out of their niche. Our finding that IFNacan activate dormant HSCs, remodel their niche and may alter interactions of HSCs with their niche may open new possibilities to combine pro-inflammatory cytokines with conventional chemotherapy for the treatment of leukemia (Essers and Trumpp, Mol.Oncol., 2010; Trumpp, Essers and Wilson, Nat.Rev.Immunol., 2010). Our data also suggest that the order and scheduling of drug treatment will be critical for the success of this approach. Using mouse models for leukemia and by testing leukemic patient samples, we are currently exploring whether combination therapy strategies with pro-inflammatory cytokines followed by classical chemotherapy can be developed which will not only eliminate the bulk of the leukemia but also target the LSCs and thus potentially cure the disease.

Leukemic stem cells (LSCs) may be targeted by combination therapy with IFNα followed by chemotherapy
© dkfz.de

Key Publications on pro-inflammatory cytokines and LSC activation:

  1. Glauche I., Horn K., Horn M., Thielecke L., Essers M.A., Trumpp A., Roeder I. (2012). Therapy of chronic myeloid leukaemia can benefit from the activation of stem cells: simulation studies of different treatment combinations. Br. J. Cancer 106: pp1742-52
  2. Essers M.A., and Trumpp A. (2010). Targeting leukemic stem cells by breaking their dormancy. Mol. Oncol. 4: 443-450
  3. Trumpp A., Essers M.A.G., and Wilson A. (2010). Awakening dormant hematopoietic stem cells. Nat Rev Immunol. 10: 201-209

to top
powered by webEdition CMS